Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus + blomia tropicalis depigmented modified allergen extract
- Development stage
- Phase 2
- Lead developer
- Leti Pharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dermatophagoides pteronyssinus + Blomia tropicalis depigmented modified allergen extract is a subcutaneous allergen immunotherapy (SCIT) product developed by Laboratorios LETI S.L.U. under the Depigoid brand. It consists of a mixture of allergen extracts from two house dust mite species, *Dermatophagoides pteronyssinus* and *Blomia tropicalis*, which have undergone depigmentation and polymerization (modification) to form allergoids. This chemical modification is designed to reduce the allergen's IgE-binding capacity, thereby improving safety and allowing for a rush build-up dosing schedule, while preserving its ability to induce a protective T-cell mediated immune response. The product is indicated for the treatment of allergic rhinitis, rhinoconjunctivitis, and controlled allergic asthma in patients sensitized to these mites, aiming to induce long-term immunological tolerance.
- Brand names
- Depigoid
- Other names
- Dermatophagoides pteronyssinus + Blomia tropicalis depigmented modified allergen extractDepigoid Dpt/BtDpt/Bt depigmented modified allergen extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus + blomia tropicalis depigmented modified allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus + blomia tropicalis depigmented modified allergen extract.